Fennec製藥 FENC 深 滬
已收盤 05-08 16:00:00 美东时间
6.93
+0.030
+0.43%
華盛通- 最 高7.25
- 今 開6.94
- 成交量 21.11万股
- 最 低 6.895
- 昨 收 6.90
- 總市值 2.41亿
- 52周最高 9.92
- 市盈率 靜 --
- 換手率 0.61%
- 52周最低 5.65
- 委 比 72.02%
- 總股本 3471.28万
- 歷史最高 14.986
- 量 比 1.32
- 振 幅 5.14%
- 歷史最低 3.255
- 每 手 1
- 風險率 0.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Fennec Pharmaceuticals Inc. will release its Q1 2026 financial results on May 14, 2026, before U.S. markets open. A conference call and webcast at 8:30 a.m. ET will discuss the results. The webcast can be accessed via www.fennecpharma.com. Fennec, focused on reducing ototoxicity in cancer patients, commercializes PEDMARK®. It received FDA approval in 2022 and European Commission approval in 2023. In 2024, Fennec partnered with Norgine for PEDMARQ...
05-07 10:36
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target
Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.
04-16 21:29
Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~~ This New Study and Other Independent, Institution-Led Research
04-07 19:12
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fennec Pharmaceuticals granted 377,500 incentive stock options to 24 new non-executive employees under its 2026 Equity Inducement Plan. The options, with an exercise price of $5.77 per share, vest over three years and have a 10-year term. The company focuses on reducing cisplatin-induced ototoxicity in cancer patients through its FDA-approved PEDMARK® and its European version PEDMARQSI®.
03-31 10:00
Fennec Pharmaceuticals Signals Costly Push Toward Growth
Fennec Pharmaceuticals (($TSE:FRX)) has held its Q4 earnings call. Read on for ...
03-28 08:23
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
Fennec Pharmaceuticals Q4 EPS $(0.17) Misses $0.04 Estimate, Sales $13.777M Miss $13.993M Estimate
Fennec Pharmaceuticals (TSX:FRX) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.04 by 572.22 percent. This is a 183.33 percent decrease over losses of $(0.06) per share
03-24 19:04
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.
03-24 04:40
Fennec Pharmaceuticals Settles PEDMARK Patent Litigation With Cipla; Blocking Generic Entry Until September 2033
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them
03-16 20:13
